Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.55 |
| ▸ | CA2 | P00918 | 6/20 | 0.55 |
| ▸ | CA9 | Q16790 | 5/20 | 0.55 |
| ▸ | CA12 | O43570 | 4/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.55 |
| ▸ | CA3 | P07451 | 3/20 | 0.55 |
| ▸ | CA4 | P22748 | 3/20 | 0.55 |
| ▸ | CA6 | P23280 | 3/20 | 0.55 |
| ▸ | CA5A | P35218 | 3/20 | 0.55 |
| ▸ | CA7 | P43166 | 3/20 | 0.55 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 2/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28313032 | 0.93 | ALDH1A1 (0.52) | CA1CA2CA9CA12CA14 | |
| Nitrobenzene SCHEMBL28829609 | 0.89 | LMNA (0.57) | CA1CA2CA9CA12CA14 | |
| SCHEMBL14574853 | 0.86 | CA2 (0.50) | CA1CA2CA9CA12CA14 | |
| SCHEMBL821155 | 0.86 | CA1 (0.50) | CA1CA2CA9CA12CA14 | |
| Nitrobenzene SCHEMBL27503832 | 0.84 | ACHE (0.53) | CA2CA9CA12HSD17B10ACHE | |
| SCHEMBL29488753 | 0.83 | CA2 (0.59) | CA1CA2CA9CA12CA14 | |
| SCHEMBL997443 | 0.83 | CA2 (0.59) | CA1CA2CA9CA12CA14 | |
| SCHEMBL777482 | 0.82 | PKM (0.46) | CA1CA2CA9CA12POLB | |
| SCHEMBL14391651 | 0.82 | POLB (0.40) | CA1CA2CA9CA12CA14 | |
| SCHEMBL15003888 | 0.82 | POLB (0.37) | CA1CA2CA9CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 403 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4228655-B1 | TETRACYCLINE DERIVATIVES FOR TREATING NEURODEGENERATIVE OR NEUROINFLAMMATORY DISEASES | INST DU CERVEAU ET DE LA MOELLE EPINIERE (FR) | 2025-08-27 | — | — | EP | claimed |
| CN-118184531-A | 1-Carboxyl-N, N, N-trimethylhexane-3-ammonium salt and preparation method thereof | 合肥瀚微生物科技有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-117820150-A | 2-carboxyl-N, N, N-trimethylbutane-1-amine and preparation method thereof | 合肥瀚微生物科技有限公司 | 2024-04-05 | — | — | CN | claimed |
| CN-117820152-A | 1-carboxyl-N, N, N-trimethylbutane-1-amine and preparation method thereof | 合肥瀚微生物科技有限公司 | 2024-04-05 | — | — | CN | claimed |
| CN-117820151-A | 1-carboxyl-N, N, N,2-tetramethyl propane-1-amine and preparation method thereof | 合肥瀚微生物科技有限公司 | 2024-04-05 | — | — | CN | claimed |
| US-20240059678-A1 | Synthesis Method for Aminopyrimidine FAK Inhibitor Compound | HINOVA PHARMACEUTICALS INC. (CN) | 2024-02-22 | — | — | US | claimed |
| EP-4324928-A1 | SYNTHETIC REAGENTS FOR ENZYME-CATALYSED ALKYLATION | Universität Basel (CH) | 2024-02-21 | — | — | EP | claimed |
| CN-117510353-A | Preparation method of 4- (trimethylammonium) valeric acid | 合肥瀚微生物科技有限公司 | 2024-02-06 | — | — | CN | claimed |
| WO-2024022426-A1 | METHOD FOR PREPARING 4-(TRIMETHYLAMMONIO)PENTANOATE | 合肥瀚微生物科技有限公司 | 2024-02-01 | — | — | WO | claimed |
| US-20230390309-A1 | TETRACYCLINE DERIVATIVES FOR TREATING NEURODEGENERATIVE OR NEUROINFLAMMATORY DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-12-07 | — | — | US | claimed |
| US-8163903-B2 | Process for the preparation of N-[5-(3-dimethylamino-acryloyl)-2-fluoro-phenyl]-N-methyl-acetamide | INTERQUIM, S.A. (ES) | 2012-04-24 | — | — | US | claimed |
| EP-2387557-A1 | PROCESS FOR THE PREPARATION OF N-[5-(3-DIMETHYLAMINO-ACRYLOYL)-2-FLUORO-PHENYL]-N-METHYL-ACETAMIDE | Interquim, S.A. (ES) | 2011-11-23 | — | — | EP | claimed |
| US-20110275809-A1 | PROCESS FOR THE PREPARATION OF N-[5-(3-DIMETHYLAMINO-ACRYLOYL)-2-FLUORO-PHENYL]-N-METHYL-ACETAMIDE | INTERQUIM, S.A. (ES) | 2011-11-10 | — | — | US | claimed |
| US-20110254078-A1 | METHOD FOR DEPOSITING SILICON NITRIDE FILM, COMPUTER-READABLE STORAGE MEDIUM, AND PLASMA CVD DEVICE | TOKYO ELECTRON LIMITED (JP) | 2011-10-20 | — | — | US | claimed |
| CN-101035801-B | Process for the synthesis of quaternary ammonium steroids | RICHTER GEDEON VEGYESZET | 2010-07-28 | — | — | CN | claimed |
| WO-2010081788-A1 | PROCESS FOR THE PREPARATION OF N-[5-(3-DIMETHYLAMINO-ACRYLOYL)-2-FLUORO-PHENYL]-N-METHYL-ACETAMIDE | INTERQUIM, S.A. (ES) | 2010-07-22 | — | — | WO | claimed |
| WO-2009018368-A1 | COMBINATION TREATMENT OF NMDA (N-METHYL-D-ASPARTATE)-ENHANCER, GLYCINE TRANSPORTER INHIBITOR, D-AMINO ACID OXIDASE INHIBITOR (DAAOI) FOR NEUROPSYCHIATRIC DISORDERS | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2009-02-05 | — | — | WO | claimed |
| EP-1824827-B1 | METHOD FOR PRODUCING ONIUM SALTS COMPRISING ALKYL ANIONS OR ARYL SULFONATE ANIONS OR ALKYL ANIONS OR ARYL CARBOXYLATE ANIONS HAVING A LOW HALIDE CONTENT | MERCK PATENT GMBH (DE) | 2008-09-17 | — | — | EP | claimed |
| US-20080171853-A1 | Somatostatin antagonists | ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, THE | 2008-07-17 | — | — | US | claimed |
| CN-101035801-A | Environmentally friendly process for the synthesis of quaternary ammonium steroids | RICHTER GEDEON VEGYESZET (HU) | 2007-09-12 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059678-A1 | Synthesis Method for Aminopyrimidine FAK Inhibitor Compound | PTK2, PARP16, CDK6 | CA1 3441/4885CA2 2281/4885CA9 3182/4885 |
| US-20230390309-A1 | TETRACYCLINE DERIVATIVES FOR TREATING NEURODEGENERATIVE OR NEUROINFLAMMATORY DISEASES | SNCA, HTT, PARK7 | CA1 3594/4885CA2 3879/4885CA9 4220/4885 |
| US-20110275809-A1 | PROCESS FOR THE PREPARATION OF N-[5-(3-DIMETHYLAMINO-ACRYLOYL)-2-FLUORO-PHENYL]-N-METHYL-ACETAMIDE | GABRA5, GABRA6, GABRD | CA1 1965/4885CA2 2407/4885CA9 3175/4885 |
| US-20080171853-A1 | Somatostatin antagonists | SSTR4, SSTR5, SSTR3 | CA1 1226/4885CA2 2703/4885CA9 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.